Isis Pharma, AstraZeneca Ink Deal – Analyst Blog

By | December 15, 2012
0 Comment

Isis Pharmaceuticals Inc. ( ISIS ) and AstraZeneca ( AZN ) recently announced that they have entered into an agreement to discover and develop five new generation antisense oncology

Link:
Isis Pharma, AstraZeneca Ink Deal – Analyst Blog

Related posts:

  1. Alnylam-ISIS Venture Prices IPO – Analyst Blog
  2. AstraZeneca’s RA Drug Disappoints – Analyst Blog
  3. Mid-Day Market Update: BlackBerry 10 Release Sends Shares Lower, Isis Pharma Boosts
  4. Abbott Spins Off Pharma Business – Analyst Blog